Extracellular vesicles (EVs) are cell-derived membranous nanoparticles that are rapidly growing in popularity as therapeutic delivery vehicles. CRISPR/Cas9 ribonucleoprotein (RNP), a gene editing tool with tremendous potential as a therapeutic, currently lacks safe and effective delivery methods for gene therapies in humans. The pairing of CRISPR/Cas9 RNP and EV-based delivery vehicles for efficient genome editing could promote the development of treatment alternatives for many genetic diseases. However, EV-based CRISPR/Cas9 RNP delivery technologies face many challenges, including 1) loading sufficient levels of the CRISPR/Cas9 RNP cargo into the EVs; 2) directing the EVs to the cells which are intended for gene editing; and 3) conserving the function of CRISPR/Cas9 RNP complexes following uptake. My central hypothesis is that strategies can be utilized to engineer cells to secrete EVs loaded with CRISPR/Cas9 components, that the EVs can selectively target cells following incorporation of moieties, and that the CRISPR/Cas9 system will perform gene editing in host cells. First, the CRISPR/Cas9 RNP was enriched in EVs by a novel encapsulation mechanism. Second, gene editing in recipient cells was achieved following the incorporation of the vesicular stomatitis virus glycoprotein (VSV-G) into the membrane of EVs encapsulating CRISPR/Cas9 RNP. Finally, it was demonstrated that SARS-CoV-2 spike protein variants may be utilized as targeting moieties for the delivery of cargos, including CRISPR/Cas9 components, selectively to cells overexpressing ACE2 and TMPRSS2. Overall, this research incorporates novel strategies to overcome barriers in the development of more efficient CRISPR/Cas9 delivery systems.